Compare INSE & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSE | MDWD |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.3M | 193.3M |
| IPO Year | 2014 | 2013 |
| Metric | INSE | MDWD |
|---|---|---|
| Price | $7.01 | $17.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $13.25 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 145.8K | 99.7K |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $199,800,000.00 | N/A |
| Revenue This Year | N/A | $48.88 |
| Revenue Next Year | $4.26 | $35.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.25 | N/A |
| 52 Week Low | $6.11 | $14.90 |
| 52 Week High | $9.95 | $22.51 |
| Indicator | INSE | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 57.42 |
| Support Level | $6.84 | $16.77 |
| Resistance Level | $9.69 | $18.99 |
| Average True Range (ATR) | 0.42 | 0.92 |
| MACD | 0.06 | 0.21 |
| Stochastic Oscillator | 52.63 | 85.76 |
Inspired Entertainment Inc is a gaming technology company, supplying content, platform and other products and services to licensed online and land-based lottery, betting and gaming operators of various countries through a range of distribution channels, on a business-to-business basis. The company provides digital gaming solutions (i) on its own proprietary and secure network, which accommodates a wide range of devices, including land-based gaming machine terminals, mobile devices and online computer applications, and (ii) through third party networks. It operates in four business segments: Gaming, Virtual Sports, Interactive and Leisure. The majority of revenue is derived from the Leisure Segment, which includes the supply of the gaming and amusement machines.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.